



A Pfizer Company

SAFETY DATA SHEET

Revision date: 05-Mar-2018

Version: 1.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Gentamicin Sulfate in 0.9% Sodium Chloride Injection (Hospira, Inc.)

Trade Name: Not applicable
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira Australia Pty Ltd
11 Lexia Place
Mulgrave VIC 3170
Australia

Emergency telephone number (North America):

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number (Australia):

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

Skin Sensitization: Category 1

Reproductive Toxicity: Category 1A

US OSHA Specific - Classification

Label Elements

Signal Word: Danger
Hazard Statements: H317 - May cause an allergic skin reaction
H360 - May damage fertility or the unborn child

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P272 - Contaminated work clothing must not be allowed out of the workplace
P281 - Use personal protective equipment as required
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P363 - Wash contaminated clothing before reuse
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Gentamicin Sulfate in 0.9% Sodium Chloride
Injection (Hospira, Inc.)
Revision date: 05-Mar-2018

Page 2 of 9

Version: 1.0



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Sodium hydroxide	1310-73-2	215-185-5	Skin Corr.1A (H314)	**
Sulfuric acid	7664-93-9	231-639-5	Skin Corr. 1A (H314)	**
Gentamicin sulfate	1405-41-0	215-778-9	Repr. Cat.1A (H360) Skin Sens. 1 (H317)	<0.5

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

** to adjust pH
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:

Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

SAFETY DATA SHEET

Material Name: Gentamicin Sulfate in 0.9% Sodium Chloride
Injection (Hospira, Inc.)
Revision date: 05-Mar-2018

Page 3 of 9

Version: 1.0

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium hydroxide

SAFETY DATA SHEET

Material Name: Gentamicin Sulfate in 0.9% Sodium Chloride
Injection (Hospira, Inc.)
Revision date: 05-Mar-2018

Page 4 of 9

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

ACGIH Ceiling Threshold Limit:	2 mg/m ³
Australia PEAK	2 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELs - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL - TWAs	2 mg/m ³

Sulfuric acid

ACGIH Threshold Limit Value (TWA)	0.2 mg/m ³
Australia STEL	3 mg/m ³
Australia TWA	1 mg/m ³
Austria OEL - MAKs	0.1 mg/m ³
Belgium OEL - TWA	0.2 mg/m ³
Bulgaria OEL - TWA	0.05 mg/m ³
Cyprus OEL - TWA	0.05 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
	0.05 mg/m ³
Denmark OEL - TWA	0.05 mg/m ³
Estonia OEL - TWA	1 mg/m ³
Finland OEL - TWA	0.05 mg/m ³
France OEL - TWA	0.05 mg/m ³
Germany - TRGS 900 - TWAs	0.1 mg/m ³
Germany (DFG) - MAK	0.1 mg/m ³
Greece OEL - TWA	0.05 mg/m ³
Hungary OEL - TWA	0.05 mg/m ³
Ireland OEL - TWAs	0.05 ppm
Italy OEL - TWA	0.05 mg/m ³
Japan - OELs - Ceilings	1 mg/m ³
Latvia OEL - TWA	0.05 mg/m ³
Lithuania OEL - TWA	0.05 mg/m ³
Luxembourg OEL - TWA	0.05 mg/m ³
Malta OEL - TWA	0.05 mg/m ³
Netherlands OEL - TWA	0.05 mg/m ³
OSHA - Final PELs - TWAs:	1 mg/m ³
Poland OEL - TWA	0.05 mg/m ³
Portugal OEL - TWA	0.05 mg/m ³
Romania OEL - TWA	0.05 mg/m ³
Slovakia OEL - TWA	0.1 mg/m ³
Slovenia OEL - TWA	0.05 mg/m ³
Spain OEL - TWA	0.05 mg/m ³

SAFETY DATA SHEET

Material Name: Gentamicin Sulfate in 0.9% Sodium Chloride
Injection (Hospira, Inc.)
Revision date: 05-Mar-2018

Page 5 of 9

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Sweden OEL - TWAs	0.1 mg/m ³
Switzerland OEL -TWAs	0.1 mg/m ³
Vietnam OEL - TWAs	1 mg/m ³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Gentamicin sulfate

Pfizer Occupational Exposure Band (OEB): OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	Clear, colorless
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	Soluble
pH:	3.0-5.5
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

Sulfuric acid

No data available

Gentamicin sulfate

No data available

SAFETY DATA SHEET

Material Name: Gentamicin Sulfate in 0.9% Sodium Chloride
Injection (Hospira, Inc.)
Revision date: 05-Mar-2018

Page 6 of 9

Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Sodium hydroxide

No data available

Water for Injection

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: None

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: Accidental ingestion may cause effects similar to those seen in clinical use.

Known Clinical Effects: Ingestion of this material may cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain. allergic skin rash. Adverse effects associated with therapeutic use include effects on hearing, kidney effects, blood cell changes, fever, chills.

Acute Toxicity: (Species, Route, End Point, Dose)

Sulfuric acid

Rat Oral LD50 2140 mg/kg

Gentamicin sulfate

Rat Oral LD50 > 5000 mg/kg

Rat Para-periosteal LD50 96mg/kg

Rat Intramuscular LD50 384mg/kg

SAFETY DATA SHEET

Material Name: Gentamicin Sulfate in 0.9% Sodium Chloride
Injection (Hospira, Inc.)
Revision date: 05-Mar-2018

Page 7 of 9

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sulfuric acid

Eye Irritation Rabbit Severe

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Gentamicin sulfate

Embryo / Fetal Development Rat Intraperitoneal 375 mg/kg/day LOAEL Developmental toxicity

Prenatal & Postnatal Development Rat Subcutaneous 660 mg/kg/day LOAEL Developmental toxicity

Prenatal & Postnatal Development Rat Subcutaneous 660 mg/kg/day LOAEL Neonatal toxicity,

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Gentamicin sulfate

DNA Binding Assay *E. coli* Negative

Carcinogen Status:

The International Agency for Research on Cancer (IARC) and the United States National Toxicology Program (NTP) have classified 'occupational exposure to strong inorganic acid mists containing sulfuric acid' as a known human carcinogen. This classification applies only to sulfuric acid when generated as a mist. This classification is debated within the scientific community and there is disagreement as to whether or not a cause and effect relationship between cancer and 'occupational exposure to strong inorganic acid mists containing sulfuric acid' exists.

Sulfuric acid

IARC:

Group 1 (Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:

Persistence and Degradability:

No data available

Bio-accumulative Potential:

No data available

SAFETY DATA SHEET

Material Name: Gentamicin Sulfate in 0.9% Sodium Chloride
Injection (Hospira, Inc.)
Revision date: 05-Mar-2018

Page 8 of 9

Version: 1.0

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, ADG or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Sodium hydroxide

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	215-185-5

Sulfuric acid

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	1000 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	1000 lb

SAFETY DATA SHEET

Material Name: Gentamicin Sulfate in 0.9% Sodium Chloride
Injection (Hospira, Inc.)
Revision date: 05-Mar-2018

Page 9 of 9

Version: 1.0

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	231-639-5

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Gentamicin sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Aminoglycosides- developmental
Australia (AICS):	Present
EU EINECS/ELINCS List	215-778-9

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction
Reproductive toxicity-Cat.1A; H360 - May damage fertility or the unborn child

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

Revision date: 05-Mar-2018
Product Stewardship Hazard Communications

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet